Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 1
2007 2
2008 3
2009 2
2010 3
2011 3
2012 1
2013 2
2014 2
2015 3
2016 7
2017 9
2018 16
2019 11
2020 21
2021 22
2022 24
2023 17
2024 24
2025 20
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R. Balar AV, et al. Among authors: boormans jl. Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051177 Clinical Trial.
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial.
Necchi A, Roumiguié M, Kamat AM, Shore ND, Boormans JL, Esen AA, Lebret T, Kandori S, Bajorin DF, Krieger LEM, Niglio SA, Uchio EM, Seo HK, de Wit R, Singer EA, Grivas P, Nishiyama H, Li H, Baranwal P, Van den Sigtenhorst-Fijlstra M, Kapadia E, Kulkarni GS. Necchi A, et al. Among authors: boormans jl. Lancet Oncol. 2024 Jun;25(6):720-730. doi: 10.1016/S1470-2045(24)00178-5. Epub 2024 May 10. Lancet Oncol. 2024. PMID: 38740030 Clinical Trial.
Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guérin.
de Jong FC, Laajala TD, Hoedemaeker RF, Jordan KR, van der Made ACJ, Boevé ER, van der Schoot DKE, Nieuwkamer B, Janssen EAM, Mahmoudi T, Boormans JL, Theodorescu D, Costello JC, Zuiverloon TCM. de Jong FC, et al. Among authors: boormans jl. Sci Transl Med. 2023 May 24;15(697):eabn4118. doi: 10.1126/scitranslmed.abn4118. Epub 2023 May 24. Sci Transl Med. 2023. PMID: 37224225 Free PMC article.
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.
Klümper N, Tran NK, Zschäbitz S, Hahn O, Büttner T, Roghmann F, Bolenz C, Zengerling F, Schwab C, Nagy D, Toma M, Kristiansen G, Heers H, Ivanyi P, Niegisch G, Grunewald CM, Darr C, Farid A, Schlack K, Abbas M, Aydogdu C, Casuscelli J, Mokry T, Mayr M, Niedersüß-Beke D, Rausch S, Dietrich D, Saal J, Ellinger J, Ritter M, Alajati A, Kuppe C, Meeks J, Vera Badillo FE, Nakauma-González JA, Boormans J, Junker K, Hartmann A, Grünwald V, Hölzel M, Eckstein M. Klümper N, et al. Among authors: boormans j. J Clin Oncol. 2024 Jul 10;42(20):2446-2455. doi: 10.1200/JCO.23.01983. Epub 2024 Apr 24. J Clin Oncol. 2024. PMID: 38657187 Free PMC article.
Open versus minimal invasive radical cystectomy.
van Diepen DC, Zuiverloon TCM, Klaver SO, Boormans JL. van Diepen DC, et al. Among authors: boormans jl. Transl Androl Urol. 2020 Dec;9(6):2471-2473. doi: 10.21037/tau-20-878. Transl Androl Urol. 2020. PMID: 33457218 Free PMC article. No abstract available.
Reply by Authors.
van Kessel KEM, de Jong JJ, Ziel-van der Made ACJ, Roshani H, Haensel SM, Wolterbeek JH, Boevé ER, Oomens EHGM, van Casteren NJ, Krispin M, Boormans JL, Steyerberg EW, van Criekinge W, Zwarthoff EC. van Kessel KEM, et al. Among authors: boormans jl. J Urol. 2020 Jul;204(1):57. doi: 10.1097/JU.0000000000000786.03. Epub 2020 Apr 13. J Urol. 2020. PMID: 32282281 No abstract available.
New horizons in bladder cancer research.
Boormans JL, Zwarthoff EC, Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ. Boormans JL, et al. Urol Oncol. 2020 Dec;38(12):867-885. doi: 10.1016/j.urolonc.2018.12.014. Epub 2019 Mar 7. Urol Oncol. 2020. PMID: 30852032 Review.
Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targets.
Scholtes MP, Akbarzadeh M, Galaras A, Nakauma-Gonzáles JA, Bazrafshan A, Solanki V, Torenvliet B, Beikmohammadi L, Lozovanu V, Romal S, Moulos P, Vavouraki N, Kan TW, Algoe M, van Royen ME, Sacchetti A, van den Bosch TPP, Eussen B, de Klein A, van Leenders GJLH, Boormans JL, Hatzis P, Palstra RJ, Zuiverloon TCM, Mahmoudi T. Scholtes MP, et al. Among authors: boormans jl. Cancer Lett. 2025 Apr 1;614:217506. doi: 10.1016/j.canlet.2025.217506. Epub 2025 Jan 30. Cancer Lett. 2025. PMID: 39892702 Free article.
164 results